The Pomp Podcast
#247: James Todaro, MD on Coronavirus, What Makes it Unique, and Potential Vaccines
- COVID-19 differs from seasonal flu and previous outbreaks (SARS, Ebola) because it spreads while asymptomatic and has a higher fatality rate than seasonal influenza.
- Vaccine development realistically requires 12–18 months; existing FDA approval processes create barriers, but pandemic conditions may accelerate timelines through emergency protocols.
- Hydroxychloroquine combined with azithromycin shows early promise in French clinical trials, with one small study reporting 100% viral load reduction in 36 patients who completed treatment.
- Existing supply chains are being prioritized: China and the UK restricted chloroquine exports in February, signaling confidence in the drug's potential as a treatment.
- Three possible paths forward include: treatment or vaccine deployment, viral mutation reducing severity (like H1N1), or prolonged crisis with potential second wave in fall similar to the 1918 Spanish flu pattern.
- Italy's trajectory appears to precede the US by approximately 10 days; warm weather may slow summer transmission, but fall reinfection waves pose a risk.